Your browser doesn't support javascript.
loading
Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD.
Mirgh, Sumeet; Gokarn, Anant; Punatar, Sachin; Chichra, Akanksha; Singh, Anuj; Rajendra, Akhil; Babu Goli, Vasu; Trivedi, Bhakti; Joshi, Amit; Patkar, Nikhil; Tembhare, Prashant; Subramanian, P G; Shetty, Nitin; Chavan, Preeti; Bhat, Vivek; Gupta, Sudeep; Khattry, Navin.
Afiliación
  • Mirgh S; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
  • Gokarn A; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Punatar S; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
  • Chichra A; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Singh A; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
  • Rajendra A; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Babu Goli V; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
  • Trivedi B; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Joshi A; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
  • Patkar N; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Tembhare P; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
  • Subramanian PG; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Shetty N; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
  • Chavan P; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Bhat V; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Gupta S; Department of Anaesthesiology, Pain and Critical Care Medicine, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
  • Khattry N; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
Transpl Infect Dis ; 23(4): e13576, 2021 Aug.
Article en En | MEDLINE | ID: mdl-33523551
Recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are an immunocompromised group who are likely to develop severe complications and mortality because of coronavirus disease 2019 (COVID-19). We report here a 61-year-old male patient of primary myelofibrosis who underwent an allo-HSCT 6 years earlier, had chronic graft-versus-host disease (cGVHD) involving the liver, lung, eyes, and skin, (with recurrent episodes of pulmonary infections) who developed severe COVID-19. The patient was treated with tocilizumab, and a combination of lopinavir/ritonavir, ribavirin, interferon-ß1b. He was discharged after 31 days with full recovery. Tocilizumab, a humanized monoclonal antibody against IL6, has been shown to benefit respiratory manifestations in severe COVID19. However, this is first report, to our knowledge, of its use and benefit in a post HSCT recipient.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Tratamiento Farmacológico de COVID-19 / Enfermedad Injerto contra Huésped Límite: Humans / Male / Middle aged Idioma: En Revista: Transpl Infect Dis Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: India Pais de publicación: Dinamarca
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Tratamiento Farmacológico de COVID-19 / Enfermedad Injerto contra Huésped Límite: Humans / Male / Middle aged Idioma: En Revista: Transpl Infect Dis Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: India Pais de publicación: Dinamarca